RxDoctor Payments Data

Jared Mataska, MD

Family Medicine · Graham, TXNPI 1780033753

Payments from drug & device makers

$2,577in general payments, 2019–2025

Across 158 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$302
  • Lilly USA, LLC$288
  • Novo Nordisk$262
  • Pfizer$244
  • AbbVie$180
  • AstraZeneca$174
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$2,577100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,577 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$489,220
Medicare patients
516
Services billed
13,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$76,551
OzempicSemaglutide57$66,505
MounjaroTirzepatide53$59,702
FarxigaDapagliflozin Propanediol60$38,986
JardianceEmpagliflozin56$36,391
JanuviaSitagliptin Phosphate36$30,123
XareltoRivaroxaban43$25,944
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$20,106
RybelsusSemaglutide13$18,082
EntrestoSacubitril/Valsartan22$14,759
TrulicityDulaglutide11$12,634
SymbicortBudesonide/Formoterol Fumarate25$8,747
QternDapagliflozin/Saxagliptin Hcl13$8,383
Breo ElliptaFluticasone/Vilanterol20$7,932
MyrbetriqMirabegron13$7,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$262$84,58870 claims
PfizerEliquis$244$76,551102 claims
Lilly USA, LLCMounjaro, Trulicity$288$72,33664 claims
AstraZenecaFarxiga, Symbicort, Qtern$174$56,11698 claims
Boehringer IngelheimJardiance$126$36,39156 claims
MerckJanuvia$29$30,12336 claims
GSKTrelegy Ellipta, Breo Ellipta$108$28,03853 claims
Johnson & JohnsonXarelto$56$25,94443 claims
NovartisEntresto$302$14,75922 claims
AbbVieLinzess, Synthroid$180$9,28654 claims
Astellas Pharma US IncMyrbetriq$150$7,51313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Graham

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →